Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase 1/2 1

Status

Completed 4Terminated 3Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Genitourinary 1Dermatologic 1

Conditions

Lymphoma, T-Cell 2Prostatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × Depsipeptides × Clear all
NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

City of Hope Medical Center

Phase 2 Completed
12 enrolled 8 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00426764 2020-02-11

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Celgene

Phase 2 Completed
131 enrolled 16 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00106418 2019-11-18

A Research Study for Patients With Prostate Cancer

Celgene

Phase 2 Completed
35 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Celgene

Phase 2 Completed
102 enrolled 15 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡